[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369419-105":59,"doc-detail-369419-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","single-cell-transcriptional-analysis-reveals-the-mechanism-of-azd6738-in-hcc-immunotherapy-via-ezh2-targeting","Single-Cell Transcriptional Analysis Reveals the Mechanism of AZD6738 in HCC Immunotherapy via EZH2 Targeting","","Single-cell transcriptional analysis is used to define how AZD6738 targets EZH2 and affects hepatocellular carcinoma (HCC) immunotherapy. The study integrates network pharmacology with transcriptomic profiling to identify HCC-associated molecules and builds a prognostic model, then performs single-cell and spatial transcriptomic screening for core targets. Molecular docking, RT-PCR, and in vivo subcutaneous tumor models validate efficacy, while flow cytometry characterizes immune changes in treated tissues.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/single-cell-transcriptional-analysis-reveals-the-mechanism-of-azd6738-in-hcc-immunotherapy-via-ezh2-targeting/369419/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/single-cell-transcriptional-analysis-reveals-the-mechanism-of-azd6738-in-hcc-immunotherapy-via-ezh2-targeting/369419.png","ImageObject",300,407,{"name":92,"@type":93},"\tJames","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main objective of the study on AZD6738 in HCC?","Question",{"text":113,"@type":114},"To identify molecular targets sensitive to AZD6738 by combining network pharmacology and transcriptomic methods, and to evaluate how AZD6738 affects the tumor microenvironment and immune responses in HCC.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were core targets for AZD6738 identified and validated?",{"text":118,"@type":114},"The study used network pharmacology and transcriptomic analysis to identify HCC-associated molecules, constructed a prognostic model, applied single-cell and spatial transcriptomic analyses for target screening, and then validated efficacy with molecular docking and RT-PCR.",{"name":120,"@type":111,"acceptedAnswer":121},"What immune effects does AZD6738 produce after treatment?",{"text":122,"@type":114},"AZD6738 enhances the immune microenvironment in liver cancer, promoting CD8+ T cell proliferation and increasing their differentiation into effector memory T cells, thereby potentiating anti-tumor immune responses.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369419,1790228899,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":26,"preview_page_count":19,"preview_urls":146},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Drug Design, Development and Therapy  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nSingle-Cell Transcriptional Analysis Reveals the Mechanism of AZD6738 in HCC Immunotherapy via EZH2 Targeting  \nRen-peng Li 1–3,*, Guo-zhi Wu 1–3,*, Xi-dong Fang 1–3,*, Wen-wen Yang 1–3, Hui-yun Zhang 1–3, Han-xun Yue 1–3, Ya Zheng2,3, Yu-ping Wang 2,3, Yong-ning Zhou2,3  \n1The First Clinical Medical College, Lanzhou University, Lanzhou, People’s Republic of China; 2Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, People’s Republic of China; 3Gansu Province Clinical Research Center for Digestive Diseases, The First Hospital of Lanzhou University, Lanzhou, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Yong-ning Zhou; Yu-ping Wang, Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, Gansu, 730000, People’s Republic of China, Email [zhouyn@lzu.edu.cn](zhouyn@lzu.edu.cn); [wangyuping@lzu.edu.cn](wangyuping@lzu.edu.cn)  \n\n| Objective: This study aims to identify specific molecular targets sensitive to AZD6738 through the integration of network pharmacology and transcriptomic methods, and to assess their potential role in the treatment of hepatocellular carcinoma (HCC) . Additionally, we explore the specific effects ofAZD6738 on the tumor microenvironment and its ability to regulate immune responses. Methods: We employed a combination of network pharmacology and transcriptomic analysis to identify specific molecules associated with HCC, including EZH2, CCNB1, PRKDC, CTSL, PSEN1, SLC6A3, and FKBP1A. Using these molecules and clinical features, we constructed a robust prognostic model for HCC. We further used single-cell transcriptomic technology to screen for core targetsand performed spatial transcriptomic analysis to determine their spatial distribution. To validate the efficacy of AZD6738 in vivo, we established a subcutaneous tumor model, with the experimental group receiving oral administration of AZD6738 (75 mg/kg) . Finally, we assessed the changes in the immune cell expression profile in tumor tissues post-AZD6738 treatment using flow cytometry. Results: Our study indicates that the high expression of genes such as EZH2, CCNB1, PRKDC, and PSEN1 is associated with poor prognosis in HCC patients. Molecular docking and RT-PCR validation demonstrated that AZD6738 exhibits high affinity for these targets and significantly reduces the mRNA levels of EZH2, PRKDC, and CCNB1 in HCC cell lines, with EZH2 showing the most pronounced decrease. Animal experiments revealed that AZD6738 can enhance the immune microenvironment in liver cancer; specifically, AZD6738 not only promotes the proliferation of CD8+ T cells but also enhances their differentiation into effector memory T cells, indicating that the drug can potentiate anti-tumor immune responses.\u003Cbr>Conclusion: This study reveals that AZD6738 demonstrates significant therapeutic efficacy by targeting the key molecule EZH2, thereby modulating the tumor microenvironment and enhancing anti-tumor immunity.\u003Cbr>Keywords: hepatocellular carcinoma, AZD6738, molecular docking, targeted therapy |\n| --- |\n| Introduction\u003Cbr>Hepatocellular carcinoma (HCC) stands as the fifth most prevalent malignancy globally and ranks as the second principal contributor to cancer-related mortality.1,2 HCC is one of several subtypes of primary liver cancer (PLC), which also includes intrahepatic cholangiocarcinoma (iCCA), mixed hepatocellular-cholangiocarcinoma (HCC-iCCA), and other rare forms such as fibrolamellar carcinoma and hepatic angiosarcoma.3,4 Each subtype presents distinct biological characteristics and therapeutic challenges.5 HCC primarily arises from hepatocytes and is often associated with chronic liver diseases like hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, alcoholic liver disease (ALD), and nonalcoholic fatty liver disease (NAFLD) .6 In contrast, iCCA originates from the epit","cbCaiioitP6ifZCR","https://ap.wps.com/l/cbCaiioitP6ifZCR","pdf",24843369,24,"English","# Introduction\n# Objective\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What is the main objective of the study on AZD6738 in HCC?\",\"answer\":\"To identify molecular targets sensitive to AZD6738 by combining network pharmacology and transcriptomic methods, and to evaluate how AZD6738 affects the tumor microenvironment and immune responses in HCC.\"},{\"question\":\"How were core targets for AZD6738 identified and validated?\",\"answer\":\"The study used network pharmacology and transcriptomic analysis to identify HCC-associated molecules, constructed a prognostic model, applied single-cell and spatial transcriptomic analyses for target screening, and then validated efficacy with molecular docking and RT-PCR.\"},{\"question\":\"What immune effects does AZD6738 produce after treatment?\",\"answer\":\"AZD6738 enhances the immune microenvironment in liver cancer, promoting CD8+ T cell proliferation and increasing their differentiation into effector memory T cells, thereby potentiating anti-tumor immune responses.\"}]","Single-Cell Transcriptional Analysis Reveals the Mechanism of AZD6738 in HCC Immunotherapy via EZH2 Targeting | PDF",1790182571,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ceaef66db99c8a6d6e2881a97d60d8c8.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83d962cadf2e2733bf12de46a3147d60.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7c6797c14feb5ae3f78251ab025f239.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73d1165db85b1ae39bc052f774b0daf4.webp",980,1268]